Clinical Trials · NCT02683941

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

Name: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 3Lanreotide

Phase: Phase 3
Recruitment status: Terminated
Sponsor: Ipsen
Enrollment: 77
Start date: Mar 2017
Locations: 57 sites, 11 countries
Primary endpoint: Median Progression-Free Survival (PFS) Time in Subjects Randomised to Lanreotide in the Double-Blind Phase or Open-Label Treatment Phase, Assessed by Central Review

View Lanreotide compound reference